Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1623 - Metastatic colorectal signet-ring cell carcinoma : clinical, histological and molecular description from an AGEO French multicenter retrospective cohort


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Pathology/Molecular Biology

Tumour Site

Colon and Rectal Cancer




Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


M. ALLART-SAVA1, F. Le Roy2, S. Kim3, D. Sefrioui4, C. Mariette5, A. Zaanan6, B.J. Rousseau7, M. Ben Abdelghani8, C. De La Fouchardière9, W. Cacheux10, R. Legros11, S. Louafi12, D. Tougeron13, N. Fares14, G. Roquin15, A.L. Bignon Bretagne16, M. Maillet17, B. Tchoundjeu18, A. Pozet19, V. Hautefeuille1

Author affiliations

  • 1 Gastroenterology, Amiens University Hospital, 80054 - Amiens/FR
  • 2 Gastroenterology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 3 Medical Oncology, Besançon University Hospital, Jean Minjoz Hospital, 25030 - Besançon/FR
  • 4 Gastroenterology, Rouen University Hospital - Charles Nicolle, 76031 - Rouen/FR
  • 5 Dpt Of Digestive And Oncological Surgery, Lille University Hospital - Claude Huriez, 59037 - Lille/FR
  • 6 Gastroenterology, European George Pompidou Hospital, 75015 - Paris/FR
  • 7 Gastroenterology, Henri-Mondor University Hospital, 94010 - Créteil/FR
  • 8 Gastroenterology, Paul Strauss Center Hospital, 67065 - Strasbourg/FR
  • 9 Gastroenterology, Leon Berard Center Hospital, 69373 - LYON/FR
  • 10 Gastroenterology, René Huguenin Hospital - Curie Institute, 92210 - St. Cloud/FR
  • 11 Gastroenterology, Limoges University Hospital, 87000 - Limoges/FR
  • 12 Gastroenterology, Longjumeau Center Hospital, 91161 - Longjumeau/FR
  • 13 Gastroenterology, Poitiers University Hospital - Jean Bernard Hospital, 86021 - Poitiers/FR
  • 14 Gastroenterology, Toulouse University Hospital, 31000 - Toulouse/FR
  • 15 Gastroenterology, Angers University Hospital, 49933 - Angers/FR
  • 16 Gastroenterology, Caen University Hospital, 14033 - Caen/FR
  • 17 Gastroenterology, Saint-Louis Hospital, 75000 - Paris/FR
  • 18 Gastroenterology, Orleans University Hospital, 45000 - Orléans/FR
  • 19 Biostatistics, Besançon University Hospital, 25000 - Besançon/FR

Abstract 1623


Metastatic colorectal signet ring cell carcinoma (mSRCRC) is a rare entity and data are limited, concerning small number of patients. Chemosensitivity for metastatic disease has never been assessed. This study analyzes their chemosensitivity and investigates their clinicopathological, molecular and prognostic characteristics.


This nationwide retrospective study included patients with mSRCRC from 2003 to 2017 in 31 french centers. They were divided into three groups: curative care (group 1), palliative chemotherapy (group 2) and best supportive care (group 3).


Data on 204 patients were collected. Median age was 63 years. Tumors were more frequent in proximal colon (46%) and rectum (29%), were T4 (71%) and poorly differenciated (86%). Sites for metastases were mainly peritoneum (69%), lymph nodes (28%) and liver (23%). Microsatellite instability (MSI) and BRAF V600E mutation were found in 19% (21/108) and 9% (9/103) of patients, and were mainly right sided (respectively 27% and 12% respectively). BRAF mutation was found in 19% of MSI tumors. RAS mutation was found in 23% (29/127) and did not vary with side. Median overall survival (mOS) was 10,1 months (95%CI = [7.9;12.8]). mOS for group 1 (n = 38), group 2 (n = 112) and group 3 (n = 54) were 45,1 months, 10,9 months and 1,8 months. No difference in mOS was found between tumor location, signet ring cell's percentage and MSI status (p = 0,13; p = 0,40 and p = 0,82). In group 2, first-line treatment (1L) was antiVEGF-based in 28,4% and antiEGFr-based in 22% of cases. Response and control rates were 13,2% and 50% respectively in 1L. Progression-free survival (PFS) was 5 months with biotherapy and 3,9 months with cytotoxics alone (p = 0,016). There was no difference in PFS between antiVEGF and antiEGFr (p = 0,8) in 1L, and between right-sided (p = 0,275) and left-sided (p = 0,265) tumors.


This large cohort of mSRCRC shows poor prognosis, specific location and molecular alterations which provides low chemosensitivity. Microsatellite analysis should be done regarding promising results of immunotherapy in MSI-high tumors.

Clinical trial identification

Legal entity responsible for the study

AGEO (Association des Gastroentérologues Oncologues).


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.